| In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs RA Thompson, EM Isin, Y Li, L Weidolf, K Page, I Wilson, S Swallow, ... Chemical research in toxicology 25 (8), 1616-1632, 2012 | 233 | 2012 |
| Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations J Gabrielsson, H Dolgos, PG Gillberg, U Bredberg, B Benthem, G Duker Drug discovery today 14 (7-8), 358-372, 2009 | 108 | 2009 |
| Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development RA Thompson, EM Isin, Y Li, R Weaver, L Weidolf, I Wilson, A Claesson, ... Chemico-biological interactions 192 (1-2), 65-71, 2011 | 99 | 2011 |
| Translational medicine guide transforms drug development processes: the recent Merck experience H Dolgos, M Trusheim, D Gross, JP Halle, J Ogden, B Osterwalder, ... Drug Discovery Today 21 (3), 517-526, 2016 | 67 | 2016 |
| The right compound in the right assay at the right time: an integrated discovery DMPK strategy P Ballard, P Brassil, KH Bui, H Dolgos, C Petersson, A Tunek, ... Drug metabolism reviews 44 (3), 224-252, 2012 | 63 | 2012 |
| Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them SA Peters, H Dolgos Clinical pharmacokinetics 58 (11), 1355-1371, 2019 | 55 | 2019 |
| Evaluating the role of solubility in oral absorption of poorly water‐soluble drugs using physiologically‐based pharmacokinetic modeling C Fink, D Sun, K Wagner, M Schneider, H Bauer, H Dolgos, K Mäder, ... Clinical Pharmacology & Therapeutics 107 (3), 650-661, 2020 | 52 | 2020 |
| Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development FH Karlsson, S Bouchene, C Hilgendorf, H Dolgos, SA Peters Drug Metabolism and Disposition 41 (12), 2033-2046, 2013 | 46 | 2013 |
| Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development SA Peters, PE Schroeder, N Giri, H Dolgos Drug Metabolism and Disposition 40 (8), 1495-1507, 2012 | 46 | 2012 |
| Investigation of sarizotan’s impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial S Krösser, R Neugebauer, H Dolgos, M Fluck, KL Rost, A Kovar European journal of clinical pharmacology 62, 277-284, 2006 | 41 | 2006 |
| In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug … RS Thelingwani, SP Zvada, H Dolgos, ALB Ungell, CM Masimirembwa Drug metabolism and disposition 37 (6), 1286-1294, 2009 | 36 | 2009 |
| Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization SA Peters, AL Ungell, H Dolgos Curr Opin Drug Discov Devel 12 (4), 509-518, 2009 | 35 | 2009 |
| Comparison of methods for the prediction of human clearance from hepatocyte intrinsic clearance for a set of reference compounds and an external evaluation set T Yamagata, U Zanelli, D Gallemann, D Perrin, H Dolgos, C Petersson Xenobiotica 47 (9), 741-751, 2017 | 32 | 2017 |
| Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro L Richert, G Tuschl, C Viollon-Abadie, N Blanchard, A Bonet, B Heyd, ... Drug Metabolism and Disposition 36 (4), 702-714, 2008 | 32 | 2008 |
| A comparative evaluation of models to predict human intestinal metabolism from nonclinical data E Yau, C Petersson, H Dolgos, SA Peters Biopharmaceutics & drug disposition 38 (3), 163-186, 2017 | 31 | 2017 |
| Metabolism of Tentoxin by Hepatic Cytochrome P‐450 3A Isozymes M Delaforge, F Andre, M Jaouen, H Dolgos, H Benech, JM Gomis, ... European journal of biochemistry 250 (1), 150-157, 1997 | 26 | 1997 |
| Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors C Desbans, C Hilgendorf, M Lutz, P Bachellier, T Zacharias, JC Weber, ... Xenobiotica 44 (1), 17-27, 2014 | 16 | 2014 |
| Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies SA Peters, C Petersson, A Blaukat, JP Halle, H Dolgos Drug Discovery Today 25 (5), 909-919, 2020 | 14 | 2020 |
| Time-and NADPH-dependent inhibition of cytochrome P450 3A4 by the cyclopentapeptide cilengitide: Significance of the guanidine group and accompanying spectral changes M Bojić, L Barbero, H Dolgos, A Freisleben, D Gallemann, S Riva, ... Drug metabolism and disposition 42 (9), 1438-1446, 2014 | 13 | 2014 |
| Prediction of volume of distribution in humans: analysis of eight methods and their application in drug discovery C Petersson, O Papasouliotis, M Lecomte, L Badolo, H Dolgos Xenobiotica, 2019 | 11 | 2019 |
Sheila Annie PetersExecutive Director, Boehringer IngelheimVerified email at boehringer-ingelheim.com
